Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;1499(1):18-41.
doi: 10.1111/nyas.14377. Epub 2020 May 22.

Macrophage targeting in cancer

Martha Lopez-Yrigoyen  1 , Luca Cassetta  1 , Jeffrey W Pollard  1
Affiliations
Review

Macrophage targeting in cancer

Martha Lopez-Yrigoyen et al. Ann N Y Acad Sci. 2021 Sep.

Abstract

Tumorigenesis is not only determined by the intrinsic properties of cancer cells but also by their interactions with components of the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) are among the most abundant immune cells in the TME. During initial stages of tumor development, macrophages can either directly promote antitumor responses by killing tumor cells or indirectly recruit and activate other immune cells. As genetic changes occur within the tumor or T helper 2 (TH 2) cells begin to dominate the TME, TAMs begin to exhibit an immunosuppressive protumor phenotype that promotes tumor progression, metastasis, and resistance to therapy. Thus, targeting TAMs has emerged as a strategy for cancer therapy. To date, TAM targeting strategies have focused on macrophage depletion and inhibition of their recruitment into the TME. However, these strategies have shown limited therapeutic efficacy, although trials are still underway with combination therapies. The fact that macrophages have the potential for antitumor activity has moved the TAM targeting field toward the development of TAM-reprogramming strategies to support this antitumor immune response. Here, we discuss the various roles of TAMs in cancer therapy and their immunosuppressive properties, as well as implications for emerging checkpoint inhibitor-based immunotherapies. We review state-of-the-art TAM-targeting strategies, focusing on current ones at the preclinical and clinical trial stages that aim to reprogram TAMs as an oncological therapy.

Keywords: TAM; cancer; macrophage; reprogramming; targeting; tumor microenvironment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cassetta, L. & J.W. Pollard. 2018. Targeting macrophages: therapeutic approaches in cancer. Nat. Rev. Drug Discov. 17: 904.
    1. Mantovani, A., F. Marchesi, A. Malesci, et al. 2017. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14: 399-416.
    1. Wang, M., J. Zhao, L. Zhang, et al. 2017. Role of tumor microenvironment in tumorigenesis. J. Cancer 8: 761-773.
    1. Hibbs, J.B. 1974. Discrimination between neoplastic and non-neoplastic cells in vitro by activated macrophages. J. Natl. Cancer Inst. 53: 1487-1492.
    1. Fidler, I.J. 1988. Macrophage therapy of cancer metastasis. Ciba Found. Symp. 141: 211-222.

Publication types

MeSH terms

Substances

LinkOut - more resources